活动性癌症合并心房颤动患者直接口服抗凝药的围手术期管理
基于PAUSE研究数据,比较活动性癌症与非癌症心房颤动患者直接口服抗凝药围手术期管理及结局。活动性癌症患者更常接受高出血风险操作、DOAC中断间隔更长、术前残余DOAC水平更低;校正混杂因素后,活动性癌症是手术相关大出血的独立预测因素(OR=2.45;95%CI 1.08-5.14)。
要点
- 活动性癌症患者更常接受高出血风险操作且围手术期DOAC中断间隔更长。
- 活动性癌症是手术相关大出血的独立预测因素(OR=2.45;95%CI 1.08-5.14)。
- 活动性癌症患者术前残余DOAC水平更低且更常使用低剂量DOAC治疗。
核心结论
- 在因择期侵入性操作而中断抗凝的DOAC治疗心房颤动患者中,活动性癌症状态与手术相关大出血风险增加相关。
研究设计与样本
- 基于PAUSE研究的描述性与比较性分析,采用多变量logistic回归评估活动性癌症状态是否为出血结局的独立危险因素。
- 协变量基于生物学原理和已有知识预先选定,校正因素包括研究中心、操作类别与出血风险、血小板减少、高血压及P2Y12抑制剂使用。
主要发现
- 活动性癌症患者年龄更大(P < .001),更常出现血小板减少(P = .026)和中度肾功能不全(P = .005),更常接受低剂量DOAC治疗(P < .001)。
- 活动性癌症患者中更高比例接受高出血风险操作(P < .001),围手术期DOAC中断间隔更长(P < .001),术前残余DOAC水平更低(P = .002)。
- 校正研究中心、操作类别与出血风险、血小板减少、高血压及P2Y12抑制剂使用后,活动性癌症是手术相关大出血的独立预测因素(OR = 2.45;95% CI,1.08-5.14)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer and atrial fibrillation (AF) are common concurrent disorders. Direct oral anticoagulants (DOACs) are prescribed to prevent stroke in patients with AF. Patients with cancer often undergo invasive procedures for diagnostic or therapeutic purposes, necessitating interruption of anticoagulation. There are limited data to guide best periprocedural anticoagulation management practices in the setting of active cancer. OBJECTIVES: To describe patient characteristics, periprocedural management, and clinical outcomes in DOAC-treated patients with AF according to active cancer status. METHODS: We conducted descriptive and comparative analyses using data from the PAUSE study. Multivariable logistic regression was used to determine whether active cancer status was an independent risk factor for bleeding outcomes. Covariates were selected a priori based on biological rationale and preexisting knowledge. RESULTS: Patients with active cancer were older (P < .001), more likely to be thrombocytopenic (P = .026), have moderate renal dysfunction (P = .005), and more likely to receive low-dose DOAC therapy (P < .001). A greater proportion of patients with active cancer underwent a high-bleed-risk procedure (P < .001), with longer periprocedural DOAC-interruption intervals (P <.001) and lower preprocedural residual DOAC levels (P = .002). Active cancer was an independent predictor for surgical major bleeding (OR = 2.45; 95% CI, 1.08-5.14) after adjusting for study center, procedure category and bleed risk, thrombocytopenia, hypertension, and the use of a P2Y12 inhibitor. CONCLUSIONS: Active cancer status is associated with an increased risk of surgical major bleeding among DOAC-treated patients with AF undergoing interruption of anticoagulation for elective invasive procedures.
引用
- Shaw JR, Li N, Abdulrehman J, et al. Periprocedural management of direct oral anticoagulants in patients with atrial fibrillation and active cancer. J Thromb Haemost. 2023. PMID: 37949316. doi:10.1016/j.jtha.2023.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。